Recruiting

A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer

ClinicalTrials.gov IDNCT07321145

PhaseNA

Enrollment200

SponsorSixth Affiliated Hospital, Sun Yat-sen University

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer, Breast Surgery

About this study

Robotic surgical systems provide notable advantages including enhanced dexterity, a magnified three-dimensional high-definition view, and high-resolution imaging, thereby improving operative stability and precision. These features make robotic systems particularly suitable for procedures performed within confined operative spaces. As the breast is a solid organ without a natural cavity, robotic systems demonstrate strong adaptability for breast surgery. Robot-assisted breast-conserving surgery (RABCS) is one of the currently utilized robotic techniques in clinical breast cancer surgery. However, as robotic breast surgery remains in its early stage of development, evidence regarding the clinical outcomes of RABCS remains limited in the literature. Therefore, this study compares the surgical outcomes of endoscopic breast-conserving surgery and robot-assisted breast-conserving surgery in breast cancer patients, aiming to assess and elucidate the clinical value of RABCS.

Interventions

Procedure: Robotic breast-conserving surgery — To perform breast-conserving surgery using a robotic system, thereby validating the safety and feasibility of robotic breast-conserving surgery.
Procedure: Endoscopic breast-conserving surgery — To perform breast-conserving surgery using a endoscopic system.

Primary outcomes

Postoperative complication rate (1 month postoperatively)

Eligibility information

Inclusion Criteria: * Female patients aged 18 to 80 years * Pathologically confirmed breast cancer prior to surgery * Sufficient glandular volume with a tumor-to-breast volume ratio ≤20% * A unifocal lesion confined to the glandular tissue * Clear desire for breast conservation and willingness to undergo R-BCS or E-BCS * No evidence of distant metastasis, no involvement of the skin or chest wall * Eligibility for standard postoperative radiotherapy Exclusion Criteria: * The presence of diffuse suspicious lesions or microcalcifications for which wide local resection was unlikely to achieve adequate negative margins or satisfactory aesthetic outcomes * Bilateral breast cancer or inflammatory breast cancer * After neoadjuvant therapy, requirement for additional concurrent surgical procedures * Inability to tolerate general anesthesia or undergo surgery * Contraindications to radiotherapy or a history of prior chest wall irradiation, pregnancy- or lactation-associated breast cancer * Refuse to undergo R-BCS or E-BCS

Study locations

the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.